Clinic for Rheumatology and Clinical Immunology/Allergology, University Hospital of Bern, Bern, Switzerland.
Regional Blood Transfusion Service of the Swiss Red Cross, Bern, Switzerland.
PLoS One. 2014 Apr 21;9(4):e95339. doi: 10.1371/journal.pone.0095339. eCollection 2014.
Abacavir hypersensitivity is a severe hypersensitivity reaction which occurs exclusively in carriers of the HLA-B57∶01 allele. In vitro culture of PBMC with abacavir results in the outgrowth of abacavir-reacting CD8+ T cells, which release IFNγ and are cytotoxic. How this immune response is induced and what is recognized by these T cells is still a matter of debate. We analyzed the conditions required to develop an abacavir-dependent T cell response in vitro. The abacavir reactivity was independent of co-stimulatory signals, as neither DC maturation nor release of inflammatory cytokines were observed upon abacavir exposure. Abacavir induced T cells arose in the absence of professional APC and stemmed from naïve and memory compartments. These features are reminiscent of allo-reactivity. Screening for allo-reactivity revealed that about 5% of generated T cell clones (n = 136) from three donors were allo-reactive exclusively to the related HLA-B58∶01. The addition of peptides which can bind to the HLA-B57∶01-abacavir complex and to HLA-B58∶01 during the induction phase increased the proportion of HLA-B58∶01 allo-reactive T cell clones from 5% to 42%. In conclusion, abacavir can alter the HLA-B57∶01-peptide complex in a way that mimics an allo-allele ('altered self-allele') and create the potential for robust T cell responses.
阿巴卡韦超敏反应是一种严重的超敏反应,仅发生在 HLA-B57∶01 等位基因携带者中。用阿巴卡韦体外培养 PBMC 会导致阿巴卡韦反应性 CD8+T 细胞的扩增,这些细胞释放 IFNγ并具有细胞毒性。这种免疫反应是如何诱导的,这些 T 细胞识别什么,仍然是一个争论的问题。我们分析了在体外产生阿巴卡韦依赖性 T 细胞反应所需的条件。阿巴卡韦的反应性不依赖于共刺激信号,因为在阿巴卡韦暴露时没有观察到 DC 成熟或炎症细胞因子的释放。阿巴卡韦诱导的 T 细胞在没有专业 APC 的情况下出现,源自幼稚和记忆区室。这些特征使人联想到同种异体反应性。同种异体反应性筛选显示,来自三个供体的 136 个生成的 T 细胞克隆(n=136)中,约有 5%仅对相关 HLA-B58∶01 表现出同种异体反应性。在诱导阶段添加可结合 HLA-B57∶01-阿巴卡韦复合物和 HLA-B58∶01 的肽,可将 HLA-B58∶01 同种异体反应性 T 细胞克隆的比例从 5%增加到 42%。总之,阿巴卡韦可以改变 HLA-B57∶01-肽复合物,使其模拟同种异体等位基因(“改变的自身等位基因”),并产生强大的 T 细胞反应的潜力。